Email this article CLINICAL AND IMMUNOLOGICAL EVALUATION OF THE EFFECTIVENESS OF SECUKINUMAB IN PATIENTS WITH PURULENT HYDRADENITIS
- Authors: Shemshuk M.I.1, Udzhukhu V.Y.2,3, Gumennaia E.R.4, Kubylinskiy A.A.1
-
Affiliations:
- Federal State Autonomous Educational Institution of Higher Education "Pirogov Russian National Research Medical University" of the Ministry of Health of the Russian Federation
- 1.Federal State Autonomous Educational Institution of Higher Education "Russian National Research Medical University of N.I. Pirogov" Ministry of Health of the Russian Federation
- 2. Peoples' Friendship University of Russia
- Federal State Autonomous Educational Institution of Higher Education "Russian National Research Medical University of N.I. Pirogov" Ministry of Health of the Russian Federation
- Section: DERMATOLOGY
- Submitted: 30.03.2025
- Accepted: 27.06.2025
- Published: 27.07.2025
- URL: https://rjsvd.com/1560-9588/article/view/677840
- DOI: https://doi.org/10.17816/dv677840
- ID: 677840
Cite item
Full Text
Open Access
Access granted
Subscription or Fee Access
Abstract
THE AIM OF THE STUDY: was a clinical and immunological assessment of the effectiveness of secukinumab in patients with purulent hydradenitis.
MATERIALS AND METHODS: The study involved 12 patients (7 male and 5 female) aged 12 to 52 years with a diagnosis of purulent hydradenitis. The control group consisted of 20 conditionally healthy volunteers. To assess the severity of purulent hydradenitis and the dynamics of changes in the clinical symptoms of the disease during treatment, the purulent hydradenitis severity index (HSSI) was used according to the point system. T-h was studied using antibodies against CD3 and CD4. Antibodies to CD45RA and CD62L were used to study the differentiation of T-helper cells. The content of interleukins in blood serum was determined by enzyme immunoassay. A 16-week course of secukinumab was used to treat 12 patients with purulent hydradenitis.
RESULTS: In the process of applying genetically engineered therapy, positive changes in the course of the disease began to be observed a week after the start of treatment with secukinumab, which made it possible, due to further regression of efflorescence, to achieve significant clinical improvement in the course of purulent hydradenitis by the end of the 16-week course. Against the background of secukinumab therapy, normalization of the relative levels of Th17, Treg, Th17/Treg and IL-17A/IL-10 ratios in peripheral blood was observed.
CONCLUSIONS: A significant imbalance in the Th17/Treg ratio can be regarded as one of the markers of the severity of purulent hydradenitis and the basis for prescribing genetically engineered biological therapy.
Keywords
Full Text
About the authors
Marina I. Shemshuk
Federal State Autonomous Educational Institution of Higher Education "Pirogov Russian National Research Medical University" of the Ministry of Health of the Russian Federation
Author for correspondence.
Email: mshemshuk@mail.ru
ORCID iD: 0000-0002-7984-4454
SPIN-code: 9806-4362
Candidate of Medical Sciences, Associate Professor of the Department of Dermatovenereology of the Institute of Motherhood and Childhood
Russian Federation, Moscow, Russian Federation, 117513, Ostrovityanova str., 1Vladislav Yu. Udzhukhu
1.Federal State Autonomous Educational Institution of Higher Education "Russian National Research Medical University of N.I. Pirogov" Ministry of Health of the Russian Federation;2. Peoples' Friendship University of Russia
Email: sovet140011@mail.ru
ORCID iD: 0000-0002-3351-9138
SPIN-code: 2066-2303
Doctor of Medical Sciences, Professor of the Department of Dermatovenerology at the Institute of Motherhood and Childhood of the Russian National Research Medical University
Russian Federation, Moscow, Russian Federation, 117513, Ostrovityanova str., 1Elvira R. Gumennaia
Federal State Autonomous Educational Institution of Higher Education "Russian National Research Medical University of N.I. Pirogov" Ministry of Health of the Russian Federation
Email: mshemshuk@mail.ru
ORCID iD: 0000-0002-8097-2816
Dermatovenerologist, Russian Children's Clinical Hospital
Russian Federation, Moscow, Russian Federation, 117513, Ostrovityanova str., 1Alexander A. Kubylinskiy
Federal State Autonomous Educational Institution of Higher Education "Pirogov Russian National Research Medical University" of the Ministry of Health of the Russian Federation
Email: cubsalex@mail.ru
ORCID iD: 0000-0002-4645-8215
SPIN-code: 2911-5496
Candidate of Medical Sciences, Associate Professor of the Department of Dermatovenereology of the Institute of Motherhood and Childhood
Russian Federation, Moscow, Russian Federation, 117513, Ostrovityanova str., 1References
- Burova S.A., Potekaev N.N., Borodulina K.S. Purulent hydradenitis: prevalence, etiopathogenesis, comorbidity (part 1). Clinical Dermatology and venereology. 2019. Vol. 18. No. 2. pp. 111-114.
- Potekaev N.N., Burova S.A., Borodulina K.S. epidemiological and socio-hygienic features of purulent hydradenitis. Clinical dermatology and venereology. 2020. Vol. 19. No. 1. pp. 13-17.
- Saunte DML, Jemec GBE. Hidradenitis Suppurativa: Advances in Diagnosis and Treatment. JAMA. 2017; 28;318(20):2019-2032. doi: 10.1001/jama.2017.16691
- Burova S.A., Borodulina K.S. Purulent hydradenitis: issues of pathogenesis, assessment scales, treatment (part 2). Clinical Dermatology and venereology. 2019. Vol. 18. No. 3. pp. 265-269.
- Olisova O.Yu., Sokolovsky E.V., Khairutdinov V.R., Kohan M.M., Rakhmatulina M.R., Burova S.A., Kotrekhova L.P., Pirogova A.S., Araviyskaya E.R., Samtsov A.V. Purulent hydradenitis: definition, epidemiology, etiology, diagnosis (part1). Bulletin of Dermatology and Venereology. 2024.T.100. No. 2.From.18-30.
- Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020; 82(5):1045-1058.doi: 10.1016/j.jaad.2019.08.090. Epub 2019 Oct 9.
- Lowe MM, Naik HB, Clancy S, Pauli M, Smith KM, Bi Y, Dunstan R, Gudjonsson JE, Paul M, Harris H, Kim E, Shin US, Ahn R, Liao W, Hansen SL, Rosenblum MD. Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-alphatherapy. JCI Insigh. 2020; 5(19): e139932. doi: 10.1172/jci.insight.139932.
- Liu T, Li S, Ying S, Tang S, Ding Y, Li Y, Qiao J, Fang H. The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside. Front Immunol. 2020;11:594735. doi: 10.3389/fimmu.2020.594735. eCollection 2020.
- Sachen KL, Arnold Greving CN, Towne JE. Role of IL-36 cytokines in psoriasis and other inflammatory skin conditions. Cytokine. 2022:155897. doi: 10.1016/j.cyto.2022.155897. Epub 2022 Jun 6.
- Zouboulis CC, Frew JW, Giamarellos-Bourboulis EJ, Jemec GBE, Del Marmol V,…et al. Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol. 2021; 30(1):8-17.doi: 10.1111/exd.14338
- Gudjonsson JE, Tsoi LC, Ma F, Billi AC, van Straalen KR, Vossen ARJV, van der Zee HH,… et al. Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis. JCI Insight.2020; 5(19) :e139930. doi: 10.1172/jci.insight.1399.
- Wolk K, Join-Lambert O, Sabat R; Aetiology and pathogenesis of hidradenitis suppurativa. Br J Dermatol. 2020;183(6):999-1010. doi: 10.1111/bjd.19556. Epub 2020 Oct 13.
- Kurayev A, Ashkar H, Saraiya A, Gottlieb AB. Hidradenitis Suppurativa: Review of the Pathogenesis and Treatment. J Drugs Dermatol. 2016;15(8):1017-22.
- Chu CB, Yang CC, Tsai SJ. Hidradenitis suppurativa: Disease pathophysiology and sex hormones. Chin JPhysiol.2021;64(6):257-265. doi: 10.4103/cjp.cjp_67_21.
- Gao JL, Otto TS, Porter ML, Kimball AB. Hidradenitis Suppurativa: New Targets and Emerging Treatments. Am J Clin Dermatol. 2024;25(5):765-778. doi: 10.1007/s40257-024-00880-1. Epub 2024 Jul 26
- Tsai YC, Hung CY, Tsai TF. Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis. Pharmaceutics. 2023;15(5):1351. doi: 10.3390/pharmaceutics15051351.
- Guermazi D, Shah A, Yumeen S, Saliba E. The use of biologics and JAK inhibitors in the management of moderate to severe Hidradenitis Suppurativa treatment: a scoping review. Arch Dermatol Res. 2024;316(6):259. doi: 10.1007/s00403-024-03121-x.
- Martora F, Scalvenzi M, Ruggiero A, Potestio L, Battista T, Megna M. Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature. Medicina (Kaunas). 2023;59(4):801. doi: 10.3390/medicina59040801.
Supplementary files
